Jill brings finance and operations experience from roles at SIS Ventures, Hamilton & Inches, and Social Investment Scotland. She previously worked as an audit supervisor at RSM UK.
Arran Dewar
Executive Director
Arran brings venture capital and accounting experience from roles including Executive Director at SIS Ventures and Fund Manager at Inspiring Scotland. He currently serves as an Investment Consultant at the University of Strathclyde.
Harry brings investment and portfolio management experience from SIS Ventures, alongside board observation roles. He currently works as an investment banking analyst at Evercore.
Siobhan brings corporate finance and investment management experience from roles at Consilium Chartered Accountants, SIS Ventures, and Johnston Carmichael. She previously worked as a commercial accountant at Finsbury Food Group.
Eos Advisory led the Series A round alongside new and existing backers to fund international expansion and commercialisation.
"The Dxcover technology combines deep technical innovation with machine learning to radically change the diagnostic landscape. Over the last three years they have conclusively shown the accuracy and ease of use of their diagnostic test across multiple cancer indications. This is very much aligned with Eos’ approach to investing in innovation that has the potential to impact positively in people's lives. More recently the team at Dxcover have focused on building a world class international team on both sides of the Atlantic. This funding round is very much about commercialization in both the UK and the US."
The oversubscribed round was co-led by Forbion, FMC Ventures, and Corteva Inc.
"SOLASTA Bio has come a long way since we set out on this journey 3 years ago. Having established operations in the UK and US, we’ve now got an international team with outstanding competencies in technology and agribusiness and, importantly, we have developed our unique technology platform to address grower pain points. The results of our field trials have been hugely encouraging, demonstrating high efficacy of biopeptides against target insect pests, as effective or better than standard insecticides. With Series A now secured, it’s time for SOLASTA Bio to kick on to the next level and successfully hit our targets for commercialisation."
The financing round was led by SCVC with participation from a group of institutional investors and agencies.
"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."
The Edinburgh biotech uses the capital to scale its 3D bioprinted tumour models across the UK, Europe, and the US.
"Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to accelerate oncology drug development significantly."
The funding round was led by The TRICAPITAL Syndicate to expand production and commercial reach.
"Beta Bugs has supplied its industry leading products to an increasing number of established and new entrant insect farmers in the UK and international markets. The company continues to develop its outstanding HiPer-Fly® breeding programme, which has demonstrated consistent increases in Black Soldier Fly genetic performance across multiple, economically valuable production traits."
-20webclip.png)
